Daniel Richter
Family Medicine · Missouri Valley, IANPI 1730246745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $786 and has fallen 90.0% since, to $78 in 2025. Among family medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$808
- Lilly USA, LLC$447
- Novo Nordisk$385
- AbbVie$294
- Bayer$266
- GSK$155
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $808 |
| Lilly USA, LLC | 21 | $447 |
| Novo Nordisk | 18 | $385 |
| AbbVie(2 entities) | 14 | $294 |
| Bayer | 13 | $266 |
| GSK | 4 | $155 |
| Merck | 10 | $146 |
| Medicure Pharma Inc. | 1 | $135 |
| Boehringer Ingelheim | 8 | $126 |
| Amgen | 7 | $100 |
| Astellas Pharma US Inc | 5 | $85 |
| Mylan Specialty L.p. | 5 | $84 |
| Pfizer | 4 | $60 |
| Jazz Pharmaceuticals Inc. | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $52 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| Gilead | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Organon | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Novartis | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$248
- HMG-CoA reductase inhibitor.$135
- MOUNJARO$127
- FARXIGA$125
How this compares
$3,566 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $29,390 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $24,290 |
| XareltoRivaroxaban | 46 | $23,809 |
| OzempicSemaglutide | 21 | $21,778 |
| EliquisApixaban | 40 | $19,606 |
| RybelsusSemaglutide | 14 | $16,918 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $11,722 |
| MyrbetriqMirabegron | 21 | $10,250 |
| FarxigaDapagliflozin Propanediol | 13 | $8,128 |
| Atorvastatin Calcium | 297 | $3,048 |
| EntrestoSacubitril/Valsartan | 12 | $2,076 |
| Levothyroxine Sodium | 199 | $1,941 |
| Potassium Chloride | 81 | $1,677 |
| Omeprazole | 146 | $1,653 |
| Tamsulosin Hcl | 85 | $1,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $385 | $38,69635 claims |
| Boehringer IngelheimJardiance | $126 | $29,39044 claims |
| GSKTrelegy Ellipta | $155 | $24,29038 claims |
| Johnson & JohnsonXarelto | $13 | $23,80946 claims |
| PfizerEliquis | $60 | $19,60640 claims |
| Astellas Pharma US IncMyrbetriq | $85 | $10,25021 claims |
| AstraZenecaFarxiga | $808 | $8,12813 claims |
| NovartisEntresto | $12 | $2,07612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Missouri Valley
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
- Laura MoellerAmes$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.